CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 14 enrolled
Drug / intervention
Alcohol +2 moredrug
Likely dose
Alcohol 0.03 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03216954
NCT03216954Early Ph 1Completed
CompareCT.gov

A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder

William Stoops·interventional·Posted Jul 13, 2017·Updated Jan 26, 2021

In Brief

A Early Phase 1 clinical trial evaluating Alcohol, Placebos, and 1 other intervention for Alcohol Use Disorder. Completed, enrolled 14 participants across 1 site.

Detailed Summary

This study will evaluate the behavioral effects of alcohol during placebo and n-acetylcysteine maintenance using sophisticated human laboratory methods.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 13, 2017
Enrollment StartSep 15, 2017
Primary CompletionApr 23, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.0 years ago

Interventions

Alcoholdrug

During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.

Placebosdrug

Subjects will receive placebo capsules

N-acetyl cysteinedrug

Subjects will receive n-acetyl cysteine capsules